Open Access
Issue
Med Sci (Paris)
Volume 37, Number 1, Janvier 2021
Page(s) 27 - 34
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2020256
Published online 25 January 2021
  1. Archer S, Chrenek C, Swainson J. Maintenance ketamine therapy for treatment-resistant depression. J Clin Psychopharmacol 2018 ; 38 : 380–384. [CrossRef] [Google Scholar]
  2. World health organization. The global burden of disease: a 2004 update. Geneva: WHO Press, 2008. [Google Scholar]
  3. Pereira VS, Hiroaki-Sato VA. A brief history of antidepressant drug development: from tricyclics to beyond ketamine. Acta Neuropsychiatr 2018 ; 30 : 307–322. [CrossRef] [PubMed] [Google Scholar]
  4. Blier P.. Rational site-directed pharmacotherapy for major depressive disorder. Int J Neuropsychopharmacol 2014 ; 17 : 997–1008. [CrossRef] [PubMed] [Google Scholar]
  5. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a Star*D report. Am J Psychiatry 2006 ; 163 : 1905–1917. [CrossRef] [PubMed] [Google Scholar]
  6. Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009 ; 30 : 563–569. [CrossRef] [Google Scholar]
  7. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 2000 ; 47 : 351–354. [CrossRef] [PubMed] [Google Scholar]
  8. Zarate CA, Jr., Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006 ; 63 : 856–864. [CrossRef] [PubMed] [Google Scholar]
  9. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010 ; 67 : 793–802. [CrossRef] [PubMed] [Google Scholar]
  10. Zarate CA, Jr., Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012 ; 71 : 939–946. [CrossRef] [PubMed] [Google Scholar]
  11. Ibrahim L, Diazgranados N, Luckenbaugh DA, et al. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 2011 ; 35 : 1155–1159. [CrossRef] [PubMed] [Google Scholar]
  12. Dale RM, Bryant KA, Thompson NR. Metabolic syndrome rather than body mass index is associated with treatment response to ketamine infusions. J Clin Psychopharmacol 2020; 40 : 75–9. [CrossRef] [Google Scholar]
  13. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013 ; 170 : 1134–1142. [CrossRef] [PubMed] [Google Scholar]
  14. Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and Other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 2015 ; 172 : 950–966. [CrossRef] [PubMed] [Google Scholar]
  15. Aan Het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010 ; 67 : 139–145. [CrossRef] [PubMed] [Google Scholar]
  16. Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013 ; 74 : 250–256. [CrossRef] [PubMed] [Google Scholar]
  17. Rasmussen KG, Lineberry TW, Galardy CW, et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 2013 ; 27 : 444–450. [CrossRef] [PubMed] [Google Scholar]
  18. Diamond PR, Farmery AD, Atkinson S, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol 2014 ; 28 : 536–544. [CrossRef] [PubMed] [Google Scholar]
  19. Shiroma PR, Johns B, Kuskowski M, et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 2014 ; 155 : 123–129. [CrossRef] [PubMed] [Google Scholar]
  20. Cusin C, Ionescu DF, Pavone KJ, et al. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation. Aust NZ J Psychiatry 2017 ; 51 : 55–64. [CrossRef] [Google Scholar]
  21. Zheng W, Zhou YL, Liu WJ, et al. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. J Psychiatr Res 2018 ; 106 : 61–68. [CrossRef] [Google Scholar]
  22. Ionescu DF, Bentley KH, Eikermann M, et al. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: a randomized, double blind, placebo controlled trial. J Affect Disord 2019 ; 243 : 516–524. [CrossRef] [PubMed] [Google Scholar]
  23. Phillips JL, Norris S, Talbot J, et al. Single, Repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry 2019 ; 176 : 401–409. [CrossRef] [PubMed] [Google Scholar]
  24. Zanos P, Moaddel R, Morris PJ, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev 2018 ; 70 : 621–660. [CrossRef] [PubMed] [Google Scholar]
  25. Cristea IA, Naudet F. US Food and Drug Administration approval of esketamine and brexanolone. Lancet Psychiatry 2019 ; 6 : 975–977. [CrossRef] [Google Scholar]
  26. Singh JB, Daly EJ, Mathews M, et al. Approval of esketamine for treatment-resistant depression. Lancet Psychiatry 2020; 7 : 232–5. [CrossRef] [Google Scholar]
  27. Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression. JAMA Psychiatry 2018; 75. [PubMed] [Google Scholar]
  28. Canuso CM, Singh JB, Fedgchin M, et al. efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2018 ; 175 : 620–630. [CrossRef] [PubMed] [Google Scholar]
  29. Fedgchin M, Trivedi M, Daly EJ, et al. efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (Transform-1). Int J Neuropsychopharmacol 2019 ; 22 : 616–630. [CrossRef] [PubMed] [Google Scholar]
  30. Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled Study. Am J Psychiatry 2019 ; 176 : 428–438. [CrossRef] [PubMed] [Google Scholar]
  31. Zheng W, Cai DB, Xiang YQ, et al. Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies. J Affect Disord 2020; 265 : 63–70. [CrossRef] [PubMed] [Google Scholar]
  32. Ochs-Ross R, Daly EJ, Zhang Y, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-Transform-3. Am J Geriatr Psychiatry 2020; 28 : 121–41. [CrossRef] [PubMed] [Google Scholar]
  33. Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 2019 ; 76 : 893–903. [CrossRef] [PubMed] [Google Scholar]
  34. Domino EF. Taming the ketamine tiger. 1965. Anesthesiology 2010 ; 113 : 678–684. [CrossRef] [Google Scholar]
  35. Short B, Fong J, Galvez V, et al. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry 2018 ; 5 : 65–78. [CrossRef] [Google Scholar]
  36. Maeng S, Zarate CA, Jr.. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 2007 ; 9 : 467–474. [CrossRef] [PubMed] [Google Scholar]
  37. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997 ; 17 : 2921–2927. [CrossRef] [PubMed] [Google Scholar]
  38. Maeng S, Zarate CA, Jr., Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008 ; 63 : 349–352. [CrossRef] [PubMed] [Google Scholar]
  39. Abdallah CG, Adams TG, Kelmendi B, et al. Ketamine’s mechanism of action: a path to rapid-acting antidepressants. Depress Anxiety 2016 ; 33 : 689–697. [CrossRef] [PubMed] [Google Scholar]
  40. Witt K, Potts J, Hubers A, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. Aust NZ J Psychiatry 2020; 54 : 29–45. [CrossRef] [Google Scholar]
  41. Phillips JL, Norris S, Talbot J, et al. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology 2020; 45 : 606–12. [CrossRef] [PubMed] [Google Scholar]
  42. Frye MA, Blier P, Tye SJ. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J Clin Psychopharmacol 2015 ; 35 : 334–336. [CrossRef] [Google Scholar]
  43. Phillips JL, Jaworska N, Kamler E, et al. A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol. BMC Psychiatry 2020; 20 : 268. [CrossRef] [PubMed] [Google Scholar]
  44. Mathew SJ, Wilkinson ST, Altinay M, et al. Electroconvulsive therapy (ect) vs. ketamine in patients with treatment-resistant depression: the Elekt-D study protocol. Contemp Clin Trials 2019 ; 77 : 19–26. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.